Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Optimer gets the NDA rolling for C. Diff therapy fidaxomicin

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Optimer Pharmaceuticals announced Sept. 22 that it has submitted the first section of a rolling NDA for its macrocyclic antibiotic fidaxomicin to treat patients with Clostridium difficile and to prevent recurrences. Relapse is a major concern with the opportunistic disease of hospitalized patients whose intestinal flora are thrown out of balance by broad-spectrum antibiotics aimed at other bacteria. Optimer plans to complete the submission in the fourth quarter and to request priority review, which could lead to regulatory action in the second quarter of 2011. Fidaxomicin's narrow spectrum profile may eradicate C. diff selectively with minimal disruption to the normal intestinal flora, unlike the current standard of care off-label metronidazole and vancomycin, according to Optimer. Relapse rates with standard of care are 20% to 30%. Although Optimer has the lead new agent in the field, other companies are working on an answer to C. diff ( 1"Fighting C. Difficile: Beyond Optimer's Fidaxomicin," Pharmaceutical Approvals Monthly, February 2010)

You may also be interested in...



Chart: Fighting C. Difficile: Beyond Optimer's Fidaxomicin

Optimer released positive data Feb. 4 from its second pivotal Phase III trial of fidaxomicin, raising hopes that hospitals will soon have a new weapon for fighting new deadly strains of Clostridium difficile, a bacterium that occurs naturally in the gut and is ordinarily benign. Problems arise, however, when antibiotics used to treat hospital-acquired infections eliminate other resident flora, allowing novel and toxic strains of C. diff to proliferate. Outbreaks of the disease, typified by diarrhea, nausea and in severe cases, colitis, sepsis and death, have made headlines in the United Kingdom and Canada.

OTC Drug Oversight By US FDA Split Among Two Divisions In Reorganization

CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.

Verrica Ready To Target Pediatric Dermatologists With First Molluscum Therapy

Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.

Topics

UsernamePublicRestriction

Register

PS004560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel